Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kubo, M.
Right arrow Articles by Tamaki, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kubo, M.
Right arrow Articles by Tamaki, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2000; 39: 632-636
© 2000 British Society for Rheumatology

Serum KL-6 in adult patients with polymyositis and dermatomyositis

M. Kubo, H. Ihn, K. Yamane, K. Kikuchi, N. Yazawa, Y. Soma and K. Tamaki

Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Objective. To determine the serum levels of KL-6, a mucin-like high-molecular-weight glycoprotein, in polymyositis/dermatomyositis (PM/DM) patients.

Methods. Serum samples from 42 adult PM/DM patients and 38 healthy control subjects were examined using specific enzyme-linked immunosorbent assay (ELISA) systems.

Results. The serum levels of KL-6 in the PM/DM patients were significantly higher than those of the healthy controls. The elevated serum KL-6 levels correlated with the presence of interstitial lung disease (ILD) and decreased percentage diffusing capacity of carbon monoxide (%DLco) in the PM/DM patients. The serum KL-6 levels inversely correlated with %DLco and percentage vital capacity. Additionally, the serum KL-6 levels were elevated in five of the seven DM patients with malignant neoplasia.

Conclusions. These results suggest that the serum KL-6 level might be a useful serum marker for ILD and internal malignancy in PM/DM.

KEY WORDS: ELISA, Interstitial lung disease, Internal malignancy.

Correspondence to: M. Kubo, Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
Q. A. Al-Salmi, J. N. Walter, G. N. Colasurdo, M. M. Sockrider, E. O. Smith, H. Takahashi, and L. L. Fan
Serum KL-6 and Surfactant Proteins A and D in Pediatric Interstitial Lung Disease
Chest, January 1, 2005; 127(1): 403 - 407.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
H Ishii, H Mukae, J Kadota, H Kaida, T Nagata, K Abe, S Matsukura, and S Kohno
High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia
Thorax, January 1, 2003; 58(1): 52 - 57.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
H. Ihn, Y. Asano, M. Kubo, K. Yamane, M. Jinnin, N. Yazawa, M. Fujimoto, and K. Tamaki
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease
Rheumatology, November 1, 2002; 41(11): 1268 - 1272.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.